Can-Fite BioPharma (CANF) EPS (Basic) Growth (3y) (2017 - 2023)
Can-Fite BioPharma (CANF) EPS (Basic) Growth (3y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 36.73% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.51% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -38.31% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -26.87% |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 50.48% |
| Sep 30, 2023 | 86.55% |
| Jun 30, 2023 | -26.08% |
| Mar 31, 2023 | 78.43% |
| Dec 31, 2022 | 75.76% |
| Sep 30, 2022 | -333.84% |
| Jun 30, 2022 | 70.97% |
| Mar 31, 2022 | -340.64% |
| Dec 31, 2021 | 10.02% |
| Sep 30, 2021 | -27.50% |
| Jun 30, 2021 | -88.68% |
| Mar 31, 2021 | 89.68% |
| Dec 31, 2020 | 91.42% |
| Sep 30, 2020 | -26.44% |
| Jun 30, 2020 | -83.81% |
| Mar 31, 2020 | 82.88% |
| Dec 31, 2019 | -26.63% |
| Sep 30, 2019 | -98.17% |
| Jun 30, 2019 | -26.53% |
| Mar 31, 2019 | -98.00% |